Inventor
Ulrich Klar
Inventor
Berlin, DE
Overview
Patents· 66 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations35%
C07DHeterocyclic compounds22%
A61KPreparations for medical, dental or toiletry purposes15%
C07JSteroids13%
C07CAcyclic or carbocyclic compounds8%
Y02PClimate change mitigation technologies in the production or processing of goods4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
PatentTitleYear
10,981,932Macrocyclic indole derivatives202110,487,092Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors201910,428,0634H-pyrrolo[3,2-C]pyridin-4-one derivatives201910,428,0443-amino-1,5,6,7-tetrahydro-4H-indol-4-ones201910,155,00417-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases20189,717,739'17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases'20179,675,612'Substituted thiazolopyrimidines'20179,556,181'Substituted pyrazolopyrimidinylamino-indazoles'20179,540,392'Thienopyrimidines'20179,512,126'Substituted imidazopyridazines'20169,512,130'Substituted imidazopyridazines'20169,468,642'Imidazopyrazines'20169,388,140'Substituted benzimidazoles'20169,382,255'Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors'20169,296,757'Substituted benzothienopyrimidines'20169,284,317'Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors'20169,255,100'Substituted imidazopyridazines'20169,212,184'6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors'20159,206,219'17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases'20159,199,999'Substituted imidazopyrazines'20159,156,877'17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases'20159,109,004'Progesterone receptor antagonists'20159,102,701'17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-ethynylphenyl derivatives, methods for the production thereof and use thereof for treating diseases'20159,096,640'17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases'20159,096,639'17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases'20159,085,603'Progesterone receptor antagonists'20159,034,856'17-(1′propenyl)-17-3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative'20158,987,239'19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives'20158,969,328'Progesterone receptor antagonists'20158,937,058'17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivative'20158,623,850'15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative'20148,278,469'17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases'20128,207,150'17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative'20127,700,621'6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations'20107,645,891'6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations'20107,605,136'Effector conjugates, methods for their preparation and their pharmaceutical use'20097,407,975'Epothilone derivatives, method for producing same and their pharmaceutical use'20087,335,775'Effector conjugates, process for their production and their pharmaceutical use'20087,148,213'Antigestagenically active steroids with a fluorinated 17α-alkyl chain'20067,129,254'Effector conjugates, process for their production and their pharmaceutical use'20067,125,893'6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations'20067,074,829'Antiestrogens, process for their production and their pharmaceutical use'20067,001,916'Epothilon derivatives, method for the production and the use thereof as pharmaceuticals'20066,930,102'16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use'20056,806,263'Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain'20046,610,736'16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use'20036,596,713'Steroid esters and amides, process for their production and their pharmaceutical use'20036,559,181'Antiestrogens, process for their protection and their pharmaceutical use'20036,503,895'Antigestagenically active steroids with a fluorinated 17-alkyl chain'20036,316,432'Antigestagenically active steroids with a flourinated 17 .alpha.-alkyl chain'20016,166,075'Antiestrogens, process for their production and their pharmaceutical use'20006,162,920'Taxane derivatives having a pyridyl substituted C13 side chain, their preparation and their use as anti-tumor agents'20006,096,732'Steroid esters, process for their production and their pharmaceutical use'20006,025,507'Borneol derivatives, methods of manufacturing them, and their pharmaceutical use'20005,965,609'Borneol esters, process for their production, and their pharmaceutical use'19995,792,792'Borenol derivatives, process for their production and their pharmaceutical use'19985,716,989'Bicyclo›3.3.0!octane derivatives, process for their production and their pharmaceutical use'19985,625,067'Cyclopentane ether derivatives, processes for their production, and their pharmaceutical use'19975,405,988'9-substituted bicyclo[3.3.0]octane derivatives, process for their production and their pharmaceutical use'19955,376,683'.DELTA.8- and .DELTA.9-prostaglandin derivatives, process for their production and their pharmaceutical use'19945,374,745'Process for the synthesis of propargyl alcohols and their use for production of prostaglandin precursors'19945,374,654'9-substituted carbacyclin derivatives, processes for their preparation, and their use as medicinal agents'19945,235,072'2-oxabicyclo(2,2,1)heptane derivatives and pharmaceutical'19935,053,400'Novel 9-substituted carbacyclin derivatives, processes for their preparation, and their use as medicinal agents'19915,023,273'6-oxoprostaglandin E derivatives, process for their production and their pharmaceutical use'19914,971,987'New carbacycline, process for their production and their use as a drug'1990Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1990–2008Patents assigned to SCHERING AG (27)· patent assignee history
1990–2021Based in Berlin, DE· patent location history
2006Based in Belin, DE· patent location history
2012–2016Patents assigned to KLAR ULRICH (18)· patent assignee history
2012–2021Patents assigned to Bayer Pharma AG (13)· patent assignee history
2012–2016Patents assigned to BOHLMANN ROLF (9)· patent assignee history
2014–2018Patents assigned to BAYER IP GMBH (18)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SCHERING AG | 27 | 1990–2008 |
| BAYER IP GMBH | 18 | 2014–2018 |
| KLAR ULRICHself | 18 | 2012–2016 |
| Bayer Pharma AG | 13 | 2012–2021 |
| BOHLMANN ROLF | 9 | 2012–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Berlin, DE | 65 | 1990–2021 |
| Belin, DE | 1 | 2006 |